Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Trophos

This page shows the latest Trophos news and features for those working in and with pharma, biotech and healthcare.

Roche gains EU PRIME status for Spinraza rival

Roche gains EU PRIME status for Spinraza rival

Prior treatment could include olesoxime, an experimental drug Roche acquired as part of its takeover of Trophos three years ago that was abandoned earlier this year after a failed phase 2

Latest news

  • Biogen buys into Ionis' nusinersen after positive phase III trial Biogen buys into Ionis' nusinersen after positive phase III trial

    Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

  • Roche buys rare disease firm Trophos in €470m deal Roche buys rare disease firm Trophos in €470m deal

    Will take control of olesoxime for spinal muscular atrophy.  . Roche has agreed a 470m deal to buy French pharma company Trophos and its lead drug for the rare neuromuscular disease spinal ... Roche is paying 120m upfront for Marseilles-based Trophos,

  • Actelion net revenue up 18 per cent for Q2

    Actelion also confirmed it has obtained the option to purchase Trophos, a France-based clinical stage pharmaceutical company, for 10m. ... Trophos has a pipeline of new molecular entities in development for the motor neuron diseases amyotrophic lateral

  • Trophos SA Awarded $1.4mn research grant

    Agence Nationale pour la Recherche, the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development. ... Biopharmaceutical company Trophos SA is currently heading a project into the efficacy of candidate drug

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Corporate acquisition. 675. Trophos/Roche. Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury.

  • Pharma deals during January 2015 Pharma deals during January 2015

    A few days later, the acquisition of the French company, Trophos was announced which brings Olesoxime an orphan drug in phase II clinical development for spinal muscular atrophy; plus TRO 40303

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Quick links

Infographics

Multimedia